Loading patent…
AssigneeESA, Inc.
InventorWayne R. Matson
Estimating the term…
Methods for determining the inventory of small process and control molecules (The Metabolome) and the interaction of the Metabolome with the Genome and Proteome (Metabolomic databases). Methods for evaluating Metabolomic databases for biochemical markers that correlate with outcome of a disease, allow monitoring of therapy and direct therapy. Methods for evaluating Metabolomic databases for lead therapeutic molecules and target systems for therapeutic manipulation. Methods of evaluating all relationships in a Metabolomic database for outcome of disease or therapy. The methods of Metabolomic database evaluation have application to stroke. Outcome predicting and therapy directing or monitoring markers of Methylation and oxidative processes in stroke have been determined. Methylation processes have been identified as targets for therapeutic development. A novel class of potential therapeutic agents that bind to DNA have been identified in stroke.
A method and procedure for combining assays of overall biochemical profiles of EC arrays with assays of carbon column switching of specific markers of genomic and proteomic interactions with those profiles to determine metabolic differences in stroke.
A method for separating DNA from biological samples for assay of patterns of ligands and associated compounds comprising:
Methylation as an abnormal process in stroke.
Methylated and N methylated compounds as markers of stroke.
Methylated and N methylated compounds as predictors of outcome of stroke.
Methylated and N methylated compounds as monitors of therapy in stroke.
N methyl and NN dimethyl serotonins as predictors of outcome of stroke.
N methyl and NN dimethyl serotonins as therapy monitoring markers in stroke.
Methylation processes as target systems for therapeutic agents in stroke.
Compounds that suppress N methylation as therapeutic agents in stroke.
N methyl accepting compounds as therapeutic agents in stroke.
Compounds that suppress the formation of N methyl serotonins as therapeutic agents in stroke.
Shifts in the ratios of oxidative DNA damage markers 8OH2′dG and 8OHG and methylation or methylation protection markers 7MG of DNA as predictive and therapy monitoring markers in stroke.
A compound with coordinates in an electrochemical array with coordinates of 66 min dominant on ch3 as a predictive marker in stroke.
A group of compounds with coordinates in an electrochemical array of 84/4, 86/5 and 96/3 as therapeutic agents in stroke.
A group of compounds associated with DNA isolated from stroke subject samples with coordinates in an electrochemical array of 68-76 min ch9 and 10 as therapeutic targets in stroke.
Abnormalities in the Kynurinine pathway in stroke.
Long term abnormalities in the kynurinine pathway in stroke.
The kynurinine pathway as a therapeutic target for stroke.
Abnormalities in the Purine pathway in stroke.
The purine pathway as a therapeutic target in stroke.
Dependencies are inferred from the claim text.